MXiPr Stats & Data

Naming clarity reduces mix-ups: MXiPr is 3-MeO-2′-oxo-PCiPr (IUPAC: 2-(isopropylamino)-2-(3-methoxyphenyl)cyclohexan-1-one); some vendors list it as “methoxipropamine.” Verify the label and test a tiny allergy dose before real dosing. Evidence: vendor and user discussions on Bluelight.

Injectable routes: multiple community reports describe seizures at very high intramuscular doses (≈80–100 mg+). Because this compound lacks human PK/PD data and sterile formulation guidance, avoid IM/IV; if someone ignores this advice, using clinical-grade sterile technique and conservative dosing is critical. Evidence: recent user thread collating seizure reports.

CNS depressants (alcohol, opioids, benzos, GHB/GBL) markedly increase risks of blackout, aspiration, and respiratory depression with ketamine-like dissociatives; treat these combos as dangerous. Evidence: TripSit combination guidance (ketamine proxies).

Stacking dissociatives (e.g., DXM, nitrous, ketamine analogues) can amplify ataxia, delirium, hypoxia, and amnesia. If nitrous is used, keep sessions brief, seated, and spaced—heavy or repeated nitrous exposure inactivates vitamin B12 and can cause neuropathy. Evidence: TripSit combos; DrugWise/EUDA nitrous overview.

Seizure-threshold–lowering medicines (tramadol, bupropion) warrant extra caution; avoid high doses and combinations that add sleep deprivation or stimulants. Evidence: StatPearls/LiverTox monographs.

Nasal care for insufflation: finely crush, use your own clean straw, rinse with water before/after, alternate nostrils, and rest your nose to reduce bleeding and septal injury. Evidence: Hi‑Ground harm‑reduction pages.

Bladder and biliary risks: heavy/frequent arylcyclohexylamine use (well-documented for ketamine) can lead to ulcerative cystitis and, more rarely, hepatobiliary injury. Space sessions (weeks, not days), hydrate, and stop use if urinary urgency/pain or right‑upper‑quadrant pain occurs; seek medical evaluation. Evidence: StatPearls and LiverTox.

Impairment: dissociatives robustly impair coordination and judgment; plan a safe setting, sober sitter at high doses, and no driving/operating machinery until the following day. Evidence: StatPearls; DrugWise.

Drug checking: the unregulated market shows frequent mislabeling and adulteration across dissociative/stimulant categories. Use a trusted drug‑checking service where available; reagent tests are helpful but may not distinguish closely related arylcyclohexylamines. Evidence: EUDA DIMS report; Toronto Drug Checking Service.

Compulsive redosing risk: many users report rapid tolerance and habit-forming patterns similar to MXE. Set firm maximums per session and leave multi-day washouts to mitigate escalation. Evidence: Bluelight MXiPr thread.